On November 30, 2020, CureVac A.G. (the “Company”) entered into an advance purchase agreement, or APA, with the European Commission, or the EC, acting on behalf and in the name of all Member States of the European Union. The APA provides for the advance purchase by the Member States of 225 million doses of the Company’s COVID-19 vaccine candidate, or CVnCoV, to be allocated among the Member States, and the option to purchase up to an additional 180 million doses. The option may be exercised by the EC on behalf and in the name of the Member States. In order to support the Company’s accelerated efforts to develop a safe and effective vaccine, the APA provides for support to the Company’s operation in the form of two up-front payments. The first up-front payment of a mid nine-figure euro amount has already been paid by the EC on behalf of the Member States. The second up-front payment of a mid nine-figure euro amount is to be paid directly by the Member States and is due after an interim data package has been submitted by the Company to the EMA for the purpose of obtaining EU marketing authorization for CVnCoV. Such up-front payments must be used solely for the development and commercial supply of CVnCoV. The Company will be required to return any unspent amounts of the up-front payments if, among others, the Company fails to successfully develop CVnCoV or if the Company successfully develops CVnCoV, but the Company does not receive EU marketing authorization or fails to supply any doses of CVnCoV to any of the Member States by late 2021, unless the Company and the EC mutually agree to a later date. In addition, if any Member State decides to purchase additional doses pursuant to the option granted under the APA, the Company will be entitled to additional up-front payments that are not subject to such restrictions on use or return of unused amounts upon termination of the APA. The Company currently estimates the total value of the APA to be in the low 10-figure euro amount assuming no exercise of the option discussed above, but this estimate is subject to the Company’s ability to successfully deliver CVnCoV pursuant to the terms of the APA, including obtaining EU marketing authorization and establishing manufacturing capacities to supply sufficient quantities of CVnCoV.